Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$0.94.

  • Axsome Therapeutics' EPS (Basic) rose 2985.07% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.67, marking a year-over-year increase of 2902.74%. This contributed to the annual value of -$5.99 for FY2024, which is 1374.53% down from last year.
  • Latest data reveals that Axsome Therapeutics reported EPS (Basic) of -$0.94 as of Q3 2025, which was up 2985.07% from -$0.97 recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' EPS (Basic) registered a high of -$0.26 during Q1 2023, and its lowest value of -$2.13 during Q4 2023.
  • In the last 4 years, Axsome Therapeutics' EPS (Basic) had a median value of -$1.32 in 2023 and averaged -$1.27.
  • In the last 5 years, Axsome Therapeutics' EPS (Basic) soared by 7475.73% in 2023 and then tumbled by 45384.62% in 2024.
  • Over the past 4 years, Axsome Therapeutics' EPS (Basic) (Quarter) stood at -$1.43 in 2022, then tumbled by 48.95% to -$2.13 in 2023, then grew by 26.6% to -$1.56 in 2024, then skyrocketed by 39.88% to -$0.94 in 2025.
  • Its EPS (Basic) stands at -$0.94 for Q3 2025, versus -$0.97 for Q2 2025 and -$1.22 for Q1 2025.